mTOR signaling in growth control and disease
Data from observational studies, particularly population-based cohorts, are most demonstrative of risk in a real-world scenario
I just mentioned a post-diagnosis weight gain of over 10% is associated with worse outcomes, so if that 5% weight loss can be combined with additional lifestyle factors, that gets towards attenuating that weight gain that patients may see and can be meaningful in terms of patients quality of life, how they tolerate their endocrine therapies, how they feel, and their body image
Semaglutide and tirzepatide mimic this function, essentially tricking your brain into thinking that youre satisfied with smaller meal portions
How often do I need to get GLP-1 injections for weight loss
Results from these clinical studies demonstrated significant improvements in glycaemic control, as indicated by notable reductions in glycated haemoglobin levels (-1.87% to -2.59%, -20 to -28 mmol/mol)